Conquering melanoma and skin cancer
Melanoma and Skin Cancer Trials (MASC Trials) specialises in investigator-initiated melanoma and skin cancer research.
We work collaboratively with world-leading researchers to deliver clinical trials that improve melanoma and skin cancer outcomes.
Trials
Hospital
Trial Sites
Countries
Patients
Enrolled
MASC Trials 2023 Annual Scientific Meeting
23 March 2023
Brisbane Convention and Exhibition Centre
Bringing together leading figures in melanoma and skin cancer clinical trials to share the latest findings and foster further innovative research.
Clinical trials save lives - donate today
Melanoma and skin cancer do not discriminate. These cancers affect young and old, men and women, in big cities and in small towns.
Donate now and support our most promising researchers to find cures for melanoma and skin cancers, and give survivors long and healthy lives.
What We Do
MASC Trials brings together a powerful network of almost 2,000 professionals who represent the many disciplines critical to our work – oncologists, surgeons, radiation specialists, nurses, allied health professionals, health economists, statisticians, research scientists, clinical research associates, data managers, patient advocates and others.
With expert support from our Advisories and our trials staff, MASC Trials leads and designs research and clinical trial development, and provides project management for multicentre, national and international collaborations.

LATEST NEWS

Protecting volunteers working in flood and fire zones
MASC Trials, MSCAN and BlazeAid have partnered to deliver sun safety educational videos for BlazeAid volunteers so they know how to protect their skin during frontline disaster response work.

Artificial intelligence a promising tool for improving early melanoma diagnosis
Digital photography combined with artificial intelligence technology has shown promising results as a diagnostic tool for the early detection of melanoma.

Dutch melanoma patients part of Australian-led trial
Australia and The Netherlands have an alarming statistic in common – melanoma is in their top five most diagnosed cancers. Clinical teams from both countries are now contributing to the international MelMarT-II trial.